Login to Your Account

2008 Redux

ODAC Votes Against Avastin for Metastatic Breast Cancer

By Marie Powers

Thursday, June 30, 2011
Genentech Inc. came out fighting during the second day of the FDA's public hearing on its proposal to withdraw accelerated approval of Avastin (bevacizumab) for metastatic breast cancer, putting members of the Oncologic Drugs Advisory Committee and representatives from the Center for Drug Evaluation and Research on notice that the company wouldn't go away quietly.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription